Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 25 for “"Cancer vaccine"”.
-
NOVEL RNA-BASED CANCER VACCINE FOR AML IMMUNOTHERAPY
… We hypothesize that personalized mRNA cancer vaccine can be a viable treatment strategy for AML patients. Using mouse AML cell lines, we have found candidate neoepitopes within intron polyadenylation sites, retained-intron sites, and somatic mutation sites. Screen for immunogenic …
-
Engineered Anti-CD40 Agonist Antibody for Cancer Vaccine Delivery
Cancer vaccines targeting patient-derived neoantigens offer great promise for personalized cancer therapy but face challenges in achieving targeted delivery to antigen-presenting cells (APCs) to elicit robust and durable cancer-specific immune responses. We synthesized an anti-mouse CD40 …
-
Development of prostrate cancer vaccine using PAP as target antigen
… options for patients with advanced prostate cancer (PC) still remain limited and rarely curative. The prostatic acid phosphatase (PAP) is prostate specific protein over-expressed in more than 90% of prostate tumours. Although an FDA-approved vaccine for the treatment of advanced prostate …
-
Development and Characterization of an Autologous Whole Cell Breast Cancer Vaccine
… 40,000 women will die from breast cancer in the United States in 2014. About 90% of these deaths will be due to metastases, rather than the primary tumor and majority of metastases are due to the recurrence and progression of non-metastatic disease. Current adjuvant treatments, such …
-
Human Endogenous Retrovirus K As A Novel Tumor-Associated Antigen For Development of An Ovarian Cancer Vaccine
… ANTIGEN FOR DEVELOPMENT OF AN OVARIAN CANCER VACCINE </strong><em></em></p> <p>Publication No.________<br />Kiera Rycaj, B.S.<br />Supervisory Professor: Feng Wang-Johanning, Ph.D., M.D.</p> <p>Ovarian cancer (OC) is the fourth most common cancer in women, and the most lethal …
-
Development of an oral DNA anti-cancer vaccine targeting an angiogenic peptide, proadrenomedullin N-terminal 20 peptide (PAMP)
Nucleic acid-based anticancer vaccines are becoming a very active field in the fight against cancer. The goal of this thesis was to generate an oral DNA vaccine targeting the angiogenic peptide, proadrenomedullin N-terminal 20 peptide (PAMP). Methods: An expression plasmid (PcPAMP) was generated by …
-
Engineering novel antibody-based molecules to probe the role of the immunoglobulin hinge and generate a potential cancer vaccine
… a second IgG engineering approach, potential cancer vaccines that feature the Fc region of IgG fused to the tumour associated cancer-testis antigen, MAGE-A, were generated and tested. Such vaccines are designed to promote formation of immune complexes, which are preferentially taken up by …
-
Research towards novel immunotherapeutic vectors: calixarene scaffolds
… immunogenic peptide but also act as a potential cancer vaccine. The introduction presents calixarenes derivatives in the context of supramolecular chemistry. Their properties on the nanoscale allow them to be potential adjuvants for cancer immunotherapeutics.
-
Knockout of the trans-acting riboswitches in Listeria monocytogenes to disrupt downstream virulence factors
… mechanisms can be exploited to produce a cancer vaccine. Currently L. monocytogenes is being studied as a viable candidate for various other cancer vaccines and therapies. The purpose of this study is to reduce the downstream virulence factors that heavily rely on upregulation of the prfA …
-
Yeast-based vaccine approaches to cancer immunotherapy
… cells and represents a promising candidate for cancer immunotherapy development. Effective cross-presentation of antigen delivered to dendritic cells is necessary for successful induction of cellular immunity. Using a yeast vaccine model, we investigated the phagosome-to-cytosol pathway of …
-
Effects of Modified Vaccinia Virus Ankara Expressing Mesothelin and the Poxvirus Immunoregulatory A35R gene in the Treatment of Murine Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. Pancreatic tumors over-express the protein mesothelin, and therefore, it is used as a tumor target antigen for vaccine development. Our current research uses an improved Modified Vaccinia Ankara poxvirus …
-
SYNTHESIS AND STUDY OF ANTI-TUMOR VACCINES
… increasing their immunogenicity for their use as vaccine components. We hypothesized that conjugation of an L-rhamnose (Rha) moiety to a carbohydrate antigen would increase the immune response against the antigen in mice possessing anti-Rha antibodies via an antibody-dependent antigen uptake …
-
Combination of STING and TLR 7/8 agonists as vaccine adjuvants for cancer immunotherapy
Cancer vaccines have evolved as a new treatment modality to eradicate cancer and has gained in popularity since the approval of Provenge® vaccine. By activating antigen-presenting cells (APCs), which, in turn, activate innate or adaptive immune responses, immunoadjuvants have become promising tools …
-
Bacterial outer membrane vesicles (OMVs) as a platform for personalized cancer vaccines
Cancer is the second leading cause of death worldwide. Tumor cells contain several mutations that can generate neoepitopes, targets of an effective anti-cancer T cell response. Increasing evidence demonstrated that cancer vaccines targeting neoepitopes are effective and safe both in preclinical …
-
Interleukin-15 and [alpha](1,3)galactosyl-expressing vaccine combination therapy for melanoma
… hyperacute rejection, we hypothesized that human cancer cells genetically modified to express the alphaGal epitope could provide a new anti-cancer vaccine. This hypothesis was previously studied using the alpha1,3-galactosyltransferase knockout (alphaGT KO) mouse model and B16 melanoma cells …
-
T cell mediated combination immunotherapy
… to fight off a particular condition or disease. Cancer immunotherapy is the specific application of agents designed to interact or stimulate the immune system to fight off tumors. Treatments as diverse as passive antibody therapy, cytokine support, and comprehensive adoptive T cell transfer make …
-
Mismatch Repair Deficient Neoantigen and Associated Circulating T-Cell Receptor Repertoires in Lynch Syndrome
… (LS) is the most common inherited colorectal cancer (CRC) syndrome. It constitutes the perfect model to understand DNA mismatch repair deficient (MMRd) carcinogenesis, which underlies 15% of early-stage CRC. LS patients develop MMRd tumors with high loads of shared neoantigens (neoAgs), which …
-
Immune modulating functions by soypeptide lunasin in cancer immunotherapy
… is currently the mainstay of treatment for most cancer patients. Despite its efficacy in eliminating cancer cells, a high percentage of chemotherapy patients eventually relapse or suffer progression of the disease. Immunosurveillance is capable of recognizing and eliminating continuously arising …
-
Cell squeezing : a vector-free microfluidic platform for intracellular delivery of macromolecules
… described herein has been implemented in cancer vaccine applications. Some recent immunotherapies against cancer have focused on the use of dendritic cells as antigen presenting cells. These cells are capable of presenting cancer antigens to other immune cell subsets and prompting a …
-
Efficacy and Mechanism of Â-Defensin2 Fused Antigen Protein Vaccines
Vaccines which use the strategy of fusing adjuvant murine â-defensin2 (mBD2) to an antigen in order to elicit stronger anti-antigen immune responses are referred to as murine â-defensin2 (mBD2) vaccines. Previous studies have validated the potential of mBD2 vaccines, thus in this study we focus on …
Page 1 of 2